Earnings
Bristol Myers Cuts 2026 EPS Outlook To $6.35-$6.55 Even As It Lifts Revenue Guidance
Deal charges of $1,558 million swamped third-quarter earnings, pulling adjusted EPS down to $1.35 from $1.63 on 7% revenue growth.
Bristol-Myers Squibb (BMY) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Deal charges of $1,558 million swamped third-quarter earnings, pulling adjusted EPS down to $1.35 from $1.63 on 7% revenue growth.
Earnings
Chris Boerner said detail in the release must be balanced against saving data for a medical meeting, and a $2 billion savings goal is on track.
Earnings
Executives said Cobenfi must speed new patient starts, and one of 190 Zolacell patients died, as the company defended its paused CAR-T program.
Earnings
Third-quarter revenue rose 7% to $13.1 billion, but adjusted EPS guidance fell to $6.35-$6.55 from $6.75-$7.00.